Rare - RARE

Ultragenyx Pharmaceutical Stock (NASDAQ: RARE)

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock, Quote.Headers.trade-ideas

Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

cancer

Biotech

Large Cap

News

Health Care

Legal

Media

General

RARE

VTRS

Henrietta Lacks&#39; family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells.

Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs

bz_pharma_briefs

Analyst Color

Reiteration

Analyst Ratings

Movers

Trading Ideas

ALNY

BIIB

IONS

Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety profile is favorable. Phase 3 study planned for 2025.

Ionis&#39; Rare Development Disorder Drug Candidate &#39;Could Be Differentiated&#39; From Peer Ultragenyx: Analyst

movers image

Intraday Update

Markets

ADBE

BAND

BIMI

CABA

CANF

CNSP

CORT

FOXO

GANX

INAB

IONM

IRON

JFBR

KAVL

KITT

KYTX

LGVN

NAAS

NNVC

NVAX

OCUL

ONMD

PENN

POWW

RNXT

RZLT

SVMH

THMO

TWOU

WLFC

Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical Inc

WISDOMTREE ENLSANDERTH UCITS USD ETF

SuperRare - United States Dollar

CANADA RARE EARTH CP ORD by Canada Rare Earth Corp.

Canada Rare Earth Corp

RARE ELEMENT RES LTD by Rare Element Resources Ltd.

Rare Element Resources Ltd

RareX Ltd

Rareview Dynamic Fixed Income ETF

Rareview Tax Advantaged Income ETF

In the latest quarter, 10 analysts provided ratings for Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Ultragenyx Pharmaceutical, revealing an average target of $89.7, a high estimate of $116.00, and a low estimate of $45.00. Marking an increase of 1.59%, the current average surpasses the previous average price target of $88.30. 
<img src="https://www.benzinga.com/files/images/story/2024/1726855217_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Ultragenyx Pharmaceutical is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$76.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$111.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ultragenyx Pharmaceutical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ultragenyx Pharmaceutical compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Ultragenyx Pharmaceutical's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Ultragenyx Pharmaceutical's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RARE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ultragenyx Pharmaceutical analyst ratings.</a>
<h2>Delving into Ultragenyx Pharmaceutical's Background</h2>
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
<h3>Ultragenyx Pharmaceutical's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Ultragenyx Pharmaceutical's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 35.75%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Ultragenyx Pharmaceutical's net margin is impressive, surpassing industry averages. With a net margin of -89.51%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Ultragenyx Pharmaceutical's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -45.96%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Ultragenyx Pharmaceutical's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -9.0%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.09.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Ultragenyx Pharmaceutical: 10 Analysts Share Their Views

Cantor Fitzgerald analyst Kristen Kluska reiterates Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Overweight and maintains $116 price target.

Price Target

Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $116 Price Target

The family of Henrietta Lacks has filed a federal lawsuit in Maryland against Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) and Viatris Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>), alleging the companies profited unlawfully from the use of her tissue cells, known as &#8220;HeLa&#8221; cells.
The Lacks estate claims these cells, which were taken without her knowledge in the 1950s, have been crucial to the companies&#8217; drug developments without any compensation or permission granted to her estate.
Ben Crump, the Lacks family attorney, emphasized the historical exploitation of Black individuals in medical research, highlighting Lacks&#8217; story as a stark example.
The lawsuit follows previous actions against Thermo Fisher Scientific Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), which has since been settled, and ongoing litigation against Ultragenyx Pharmaceutical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>).
Related: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38968851/ultragenyx-faces-lawsuit-over-alleged-unjust-use-of-henrietta-lacks-cells" rel="noreferrer noopener">Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks&#8217; Cells</a>.
Henrietta Lacks&#8217;s cells were taken from her cervix during cancer treatment in 1951 at a Baltimore hospital.
Reuters noted that these HeLa cells were the first to survive and reproduce indefinitely in lab conditions. Lacks passed away from cervical cancer later that year at the age of 31.
The complaint details how Novartis allegedly used HeLa cells in the development of its herpes drug Famvir, cancer treatment Kymriah, and spinal muscular atrophy therapy Zolgensma.
Viatris is accused of using these cells to test its herpes drug, Denavir, and depression treatment, Mylan-Mirtazapine.
The Lacks family seeks profits from the commercialization of HeLa cells and a court order to prevent further use without permission.
Price Action: At the last check on Tuesday, NVS stock was up 0.36% at $110.25, and VTRS stock was down 0.30% at $11.53.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40168977/bristol-myers-squibb-terminates-cancer-drug-development-program-with-agenus" target="_blank" rel="noreferrer noopener">Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus</a>.</li>
</ul>
Photo via Shutterstock

Barclays analyst Gena Wang maintains Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Overweight and lowers the price target from $83 to $81.

Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $81

Goldman Sachs analyst Salveen Richter maintains Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Buy and raises the price target from $67 to $76.

Goldman Sachs Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $76

WIIM

Ultragenyx Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 revenue guidance above estimates. Also, Cantor Fitzgerald and Wedbush raised their respective price targets on the stock.

Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Overweight and raises the price target from $115 to $116.

Cantor Fitzgerald Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $116

Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Neutral and raises the price target from $43 to $46.

Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Raises Price Target to $46

Ultragenyx Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 revenue guidance above estimates.

2024 Full Year Financial Guidance
<ul>
<li>Total revenue guidance increased to be in the range of $530 million to $550 million (previously $500 million to $530 million)</li>
<li>Crysvita revenue expected to be towards the upper end of the range of $375 million to $400 million. This includes all regions where Ultragenyx will recognize revenue: product sales in Latin America and Turkey, royalties in Europe, which have been ongoing, and royalties in North America, which began in April 2023.</li>
<li>Dojolvi revenue in the range of $75 million to $80 million</li>
<li>Net Cash Used in Operations less than $400 million</li>
</ul>

Guidance

Ultragenyx Pharmaceutical Raises FY24 Revenue Guidance From $500M-$530M To $530M-$550M Vs $513.16M Est.

Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) reported quarterly losses of $(1.52) per share which beat the analyst consensus estimate of $(1.72) by 11.63 percent. This is a 32.44 percent increase over losses of $(2.25) per share from the same period last year. The company reported quarterly sales of $147.03 million which beat the analyst consensus estimate of $123.18 million by 19.36 percent. This is a 35.75 percent increase over sales of $108.31 million the same period last year.

Earnings

Earnings Beats

Ultragenyx Pharmaceutical Q2 EPS $(1.52) Beats $(1.72) Estimate, Sales $147.03M Beat $123.18M Estimate

Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wednesday, July 24, at the 2024 Angelman Syndrome Foundation (ASF) Family Conference and Research Symposium in Sandusky, Ohio.

Ultragenyx To Present GTX-102 Angelman Syndrome Program Update At The ASF Family Conference And Research Symposium On Wednesday, July 24, 2024

Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Buy and maintains $111 price target.

Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Maintains $111 Price Target

Ionis Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) released results Monday from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with <a href="https://www.benzinga.com/pressreleases/24/07/n39879430/ionis-announces-positive-detailed-results-from-the-halos-study-of-ion582-in-people-with-angelman-s" target="_blank" rel="noreferrer noopener">Angelman syndrome (AS)</a>.
AS is a rare neurodevelopmental disorder caused by a loss of function in the maternal UBE3A gene. It affects an estimated 1 in 21,000 people worldwide.
The data demonstrated consistent and encouraging clinical improvement on assessing all functional domains, including communication, cognition, and motor function measures.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/39118220/ionis-pharmaceuticals-reveals-late-stage-donidalorsen-data-analyst-says-results-sho" rel="noreferrer noopener">Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile</a>.
Overall, 97% of people in the medium and high dose groups saw an improvement in overall AS symptoms.
In the 51-patient HALOS study, ION582 showed favorable safety and tolerability at all dose levels.
Ionis plans to meet with regulators later this year to review and confirm its Phase 3 study design. This puts the company on track for a pivotal study initiation in the first half of 2025. 
William Blair writes that the update is a clear positive for Ionis, positioning ION582 as a key asset in its wholly owned portfolio after recently reacquiring sole rights from Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>).
William Blair reiterates the <a target="_blank" href="https://www.benzinga.com/quote/IONS/analyst-ratings" rel="noreferrer noopener">Outperform rating on Ionis</a>.
The analyst notes that the consistent improvements across various metrics in the robust dataset, which will likely be used as a primary endpoint for approval, boost confidence in the drug&#8217;s potential benefits.
While slightly behind a peer program from Ultragenyx Pharmaceutical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>), Ionis has largely closed the development timeline gap and could be differentiated from a safety perspective, making ION582 an attractive asset for future growth given lack of approved therapies for the indication currently.
In the meantime, investors are expected to focus on the launch of Wainua (eplontersen) in collaboration with AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), and the potential approval and launch of the wholly-owned therapies olezarsen for familial chylomicronemia syndrome (PDUFA December 19, 2024) and donidalorsen for the prophylactic treatment of HAE (NDA expected to be filed this year).
The analyst believes the next 12 to 18 months could be transformative for Ionis due to the expansion of its marketed products. They also consider the company undervalued, especially in light of the potential of TTR silencers for TTR-cardiomyopathy, following Alnylam Pharmaceuticals Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) positive <a href="https://www.benzinga.com/general/biotech/24/06/39456940/alnylams-closely-watched-phase-3-heart-disease-trial-of-vutrisiran-hits-primary-endpoint-shares-s" target="_blank" rel="noreferrer noopener">HELIOS-B trial results for vutrisiran</a>.
Price Action: IONS stock is up 4.50%, trading at $49.97 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/05/38878003/tale-of-two-ionis-partnered-neurology-focused-early-stage-assets-biogen-discontinues-one-decides-" target="_blank" rel="noreferrer noopener">Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another</a>.</li>
</ul>

Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst

14 analysts have shared their evaluations of Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $86.79, along with a high estimate of $127.00 and a low estimate of $45.00. Witnessing a positive shift, the current average has risen by 1.76% from the previous average price target of $85.29.
<img src="https://www.benzinga.com/files/images/story/2024/1721664075_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Ultragenyx Pharmaceutical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$67.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$48.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$76.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$111.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Dae Gon Ha</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$72.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$109.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Yaron Werber</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$61.00</td>
<td>$59.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ultragenyx Pharmaceutical. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ultragenyx Pharmaceutical compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Ultragenyx Pharmaceutical's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Ultragenyx Pharmaceutical's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RARE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ultragenyx Pharmaceutical analyst ratings.</a>
<h2>Get to Know Ultragenyx Pharmaceutical Better</h2>
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
<h3>Ultragenyx Pharmaceutical: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Ultragenyx Pharmaceutical's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 8.3%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Ultragenyx Pharmaceutical's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -156.83% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Ultragenyx Pharmaceutical's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -82.12%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Ultragenyx Pharmaceutical's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -12.2%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.29, Ultragenyx Pharmaceutical adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical

Cantor Fitzgerald analyst Kristen Kluska reiterates Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Overweight and maintains $115 price target.

Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $115 Price Target

Wedbush analyst Laura Chico reiterates Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Neutral and maintains $45 price target.

Wedbush Reiterates Neutral on Ultragenyx Pharmaceutical, Maintains $45 Price Target

Ultragenyx Aligns With FDA On Phase 3 Study Endpoints For GTX-102; Phase 3 Study To Initiate By Year-End; Successful End-Of-Phase 2 Meeting Supports Plans For Global Double-Blind Sham-Controlled Pivotal Study; Additional Study Planned For Patients With Other Mutations

<a href="https://endpts.com/biogen-is-pursuing-more-dealmaking-this-year-with-plans-to-spend-up-to-8B/">https://endpts.com/biogen-is-pursuing-more-dealmaking-this-year-with-plans-to-spend-up-to-8B/</a>
&nbsp;
&nbsp;

DNLI

'Biogen Is Pursuing More Dealmaking This Year, With Plans To Spend Up To $8B' - Endpoint News

As we head into the final 90 minutes of the trading session, these are today's top stock gainers: Some notable catalysts for today's movers include...

Top Stock Gainers Today – TNDM, TWLO, and More

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2024 Earnings Call Transcript

In a report released on August 2, Gena Wang from Barclays maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a pri...

Ultragenyx Pharmaceutical (RARE) Receives a Buy from Barclays

Robert W. Baird analyst Jack Allen maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report) on August 2 and set a price target...

Strong Buy Rating for Ultragenyx Pharmaceutical Amid Financial Growth and Promising Clinical Advancements

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
When the human genome was fully sequenced in 2003, the prospects of genetic medicine ushered in a new era of human health. Today, scientists and drug developers have a better understanding of the genetic drivers of disease than ever before. As such, genomics stocks present a new opportunity for investors to buy into the potential future of medicine, as nearly all modern therapies rely on understanding patient genetics to be as efficient as possible.



Moreover, genomics companies differ from traditional healthcare or <a target="_blank" href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> as they often do not rely on selling a drug to be successful. Rather, their services and relevance to the industry enable them to derive profit from supporting the broader medical industry.



For investors, this means a slower yet more stable growth stock that can help dilute portfolio risk if bought in the correct proportions. As such, here are three genomic stocks to consider due to the potential of their ongoing research and investor draw.



<h2>Sarepta Therapeutics (SRPT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/06/srpt1600-300x169.png" alt="Sarepta Therapeutics company logo displayed on mobile phone. SRPT stock"><div>Source: Piotr Swat / Shutterstock.com</div></div>From gene editing to ribonucleic acid (RNA) technologies, Sarepta Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/srpt-stock-quote/" target="_blank">SRPT</a>) has strategically positioned itself in the biotech industry to become one of the best genomics stocks to buy right now. I recommended it back in January of this year, and since then, the stock has grown 24%, with most signs pointing to continued growth.



As I&rsquo;ve discussed before, much of the company&rsquo;s success can be attributed to its narrow patient population and the broader potential of <a target="_blank" href="https://www.sarepta.com/science">its technologies</a> should they succeed in treating genetic muscular dystrophies. This presents investors with a strong competitive moat while also enabling the company to funnel research into treating other genetically driven diseases.



One particularly intriguing project the company is working on is using specially designed <a target="_blank" href="https://www.sarepta.com/science/rna-platform">RNA molecules</a> to produce proteins in target cells responsible for the disease. This would allow patients to take an injection and feel relief from certain symptoms of their genetic disease, though not completely reversing the malfunctioning cell.



<h2>Bio-Techne (TECH)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div>Bio-Techne (NASDAQ:<a target="_blank" href="https://investorplace.com/stock-quotes/tech-stock-quote/">TECH</a>) derives its value from its ability to support the broader genomics industry by specializing in workflow services and products for gene therapies and genetic research. One thing in particular that makes the company stand out is its focus on creating reputable and easily replicated processes to further research in the genetic field. No biomedical research is useful if not replicated by peers and other researchers. This aspect of medicine is critical to how researchers achieve broader industry acceptance for their products.



As such, Bio-Techne has a lot to gain from selling its products and services to the broader industry as genomics research and backing continue to grow. Thus, investors should consider a long-term position in TECH stock as it begins to recover from this year&rsquo;s share value losses.



<h2>Ultragenyx Pharmaceutical (RARE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/07/pharma-stocks-300x169.jpg" alt="rows of pills on a table representing pharmaceutical stocks. EVAX stock"><div>Source: Iryna Imago / Shutterstock.com</div></div>Known for its commitment to developing treatments for <a href="https://www.ultragenyx.com/our-research/pipeline/" target="_blank">ultra-rare genetic diseases</a>, Ultragenyx Pharmaceutical (NASDAQ:<a href="https://investorplace.com/stock-quotes/rare-stock-quote/" target="_blank">RARE</a>) has found exceptional success in gaining FDA approval for its monoclonal antibodies and enzyme replacements. As a result, the company&rsquo;s stock has grown 40% over the last 12 months, with some ups and downs along the way.



This comes from the company&rsquo;s impressive EPS and revenue beats in its second quarter compared to analyst expectations. For investors, this trend will likely continue as many of RARE&rsquo;s genetic treatments remain relatively newly approved, meaning that once they hit the market in full swing, the company could very well turn a serious profit.



Consequently, monitoring when these drugs become fully commercialized could be the key to getting in at the right time before the company becomes profitable and its price grows rapidly.



On the date of publication, Viktor Zarev&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Viktor Zarev is a scientist, researcher, and writer specializing in explaining the complex world of technology stocks through dedication to accuracy and understanding.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
The post <a href="https://investorplace.com/2024/08/3-genomics-stocks-that-may-transform-personalized-medicine/">3 Genomics Stocks That May Transform Personalized Medicine </a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Genomics Stocks That May Transform Personalized Medicine

Invesco Main Street Small Cap Fund Q2 2024 Review

Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective

Stifel Nicolaus analyst Dae Gon Ha maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report) today and set a price target of $1...

Stifel Nicolaus Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

Tracking Baker Brothers Portfolio - Q2 2024 Update

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Repo...

Ultragenyx Pharmaceutical (RARE) Gets a Buy from Bank of America Securities

ABBV

ABCL

ACAD

ADMA

AKRO

ARGNF

ARGX

ATKR

BCRX

BCYC

BEIGF

BGNE

CYRX

DAVA

EWTX

GTES

IMCR

INCY

INSM

INSP

ITRI

KYMR

MDGL

MTSI

PFSI

PYCR

PZZA

REPL

RGEN

ROIV

RVMD

RVMDW

RYTM

SKWD

SMCI

SRPT

TECH

TMDX

TNDM

TWLO

TWST

Press Releases

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program

Financing

Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium

Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update

Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update

Amlogenyx Inc. Closes Successful Seed Funding Led by GordonMD® Global Investments LP

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical (RARE) Forecast

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock, Quote.Headers.trade-ideas